Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11728181rdf:typepubmed:Citationlld:pubmed
pubmed-article:11728181lifeskim:mentionsumls-concept:C1533646lld:lifeskim
pubmed-article:11728181lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:11728181lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:11728181lifeskim:mentionsumls-concept:C0043309lld:lifeskim
pubmed-article:11728181lifeskim:mentionsumls-concept:C2267219lld:lifeskim
pubmed-article:11728181lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:11728181lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:11728181lifeskim:mentionsumls-concept:C1707689lld:lifeskim
pubmed-article:11728181pubmed:issue25lld:pubmed
pubmed-article:11728181pubmed:dateCreated2001-11-30lld:pubmed
pubmed-article:11728181pubmed:abstractTextTwo closely related classes of oxindole-based compounds, 1H-indole-2,3-dione 3-phenylhydrazones and 3-(anilinomethylene)-1,3-dihydro-2H-indol-2-ones, were shown to potently inhibit cyclin-dependent kinase 2 (CDK2). The initial lead compound was prepared as a homologue of the 3-benzylidene-1,3-dihydro-2H-indol-2-one class of kinase inhibitor. Crystallographic analysis of the lead compound bound to CDK2 provided the basis for analogue design. A semiautomated method of ligand docking was used to select compounds for synthesis, and a number of compounds with low nanomolar inhibitory activity versus CDK2 were identified. Enzyme binding determinants for several analogues were evaluated by X-ray crystallography. Compounds in this series inhibited CDK2 with a potency approximately 10-fold greater than that for CDK1. Members of this class of inhibitor cause an arrest of the cell cycle and have shown potential utility in the prevention of chemotherapy-induced alopecia.lld:pubmed
pubmed-article:11728181pubmed:languageenglld:pubmed
pubmed-article:11728181pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11728181pubmed:citationSubsetIMlld:pubmed
pubmed-article:11728181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11728181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11728181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11728181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11728181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11728181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11728181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11728181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11728181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11728181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11728181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11728181pubmed:statusMEDLINElld:pubmed
pubmed-article:11728181pubmed:monthDeclld:pubmed
pubmed-article:11728181pubmed:issn0022-2623lld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:WalkerD HDHlld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:HarrisP APAlld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:BramsonH NHNlld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:EdelsteinMMlld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:MontaniNNlld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:KuyperL FLFlld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:LovejoyBBlld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:VealJ MJMlld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:RocqueW JWJlld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:ShewchukLLlld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:HassellAAlld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:GampeR TRTJrlld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:DavisS TSTlld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:CoronaJJlld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:HunterR NRNlld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:FryeS VSVlld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:LuzzioM JMJlld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:DickersonS...lld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:HolmesW DWDlld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:LackeyK EKElld:pubmed
pubmed-article:11728181pubmed:authorpubmed-author:RusnakDDlld:pubmed
pubmed-article:11728181pubmed:issnTypePrintlld:pubmed
pubmed-article:11728181pubmed:day6lld:pubmed
pubmed-article:11728181pubmed:volume44lld:pubmed
pubmed-article:11728181pubmed:ownerNLMlld:pubmed
pubmed-article:11728181pubmed:authorsCompleteYlld:pubmed
pubmed-article:11728181pubmed:pagination4339-58lld:pubmed
pubmed-article:11728181pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:meshHeadingpubmed-meshheading:11728181...lld:pubmed
pubmed-article:11728181pubmed:year2001lld:pubmed
pubmed-article:11728181pubmed:articleTitleOxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.lld:pubmed
pubmed-article:11728181pubmed:affiliationGlaxoSmithKline Inc., Five Moore Drive, Research Triangle Park, North Carolina 27709, USA.lld:pubmed
pubmed-article:11728181pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:11728181lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11728181lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11728181lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11728181lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11728181lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11728181lld:pubmed